Alpha 2.0
Login Register
» Articles » PMID: 15150597

Lower Protection of Cytological Screening for Adenocarcinomas and Shorter Protection for Younger Women: the Results of a Case-control Study in Florence

Overview
Journal Br J Cancer
Specialty Oncology
Date 2004 May 20
PMID 15150597
Citations 33
Authors
M Zappa
C B Visioli
S Ciatto
A Iossa
E Paci
P Sasieni
Affiliations
Soon will be listed here.
Abstract

The efficacy of cytological screening in preventing adenocarcinoma of cervix uteri as compared to squamous cell cancer has been evaluated by means of a case-control study in the province of Florence. The odds ratios of women who had a Pap test within the 3 years before the index date was 0.65 (95% confidence interval (CI) 0.26-1.64) and 0.15 (95% CI 0.07-0.31), for adenocarcinoma and squamous cancer, respectively. The duration of the protective effect was shorter in women below the age of 40 years than in older women.

Citing Articles

Magnitude and trends in cervical cancer at Mbarara Regional Referral Hospital in South Western Uganda: Retrospective analysis of data from 2017-2022.

Kajabwangu R, Bajunirwe F, Izudi J, Bazira J, Farjardo Y, Ssedyabane F PLOS Glob Public Health. 2024; 4(1):e0002848.

PMID: 38241290 PMC: 10798516. DOI: 10.1371/journal.pgph.0002848.

Population-Based Trends in Cervical Cancer Incidence and Mortality in Brazil: Focusing on Black and Indigenous Population Disparities.

de Melo A, da Silva J, Dos Santos A, Thuler L J Racial Ethn Health Disparities. 2023; 11(1):255-263.

PMID: 36648624 DOI: 10.1007/s40615-023-01516-6.

Effectiveness of Cervical Testing in and outside a Screening Program-A Case-Control Study.

Pankakoski M, Sarkeala T, Anttila A, Heinavaara S Cancers (Basel). 2022; 14(21).

PMID: 36358612 PMC: 9653595. DOI: 10.3390/cancers14215193.

Recurrent or primary metastatic cervical cancer: current and future treatments.

Gennigens C, Jerusalem G, Lapaille L, De Cuypere M, Streel S, Kridelka F ESMO Open. 2022; 7(5):100579.

PMID: 36108558 PMC: 9588874. DOI: 10.1016/j.esmoop.2022.100579.

New Insights in the Diagnosis of Rare Adenocarcinoma Variants of the Cervix-Case Report and Review of Literature.

Secosan C, Balint O, Ilian A, Balan L, Balulescu L, Motoc A Healthcare (Basel). 2022; 10(8).

PMID: 36011067 PMC: 9408547. DOI: 10.3390/healthcare10081410.

References
1.
Smith H, Tiffany M, Qualls C, Key C . The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. Gynecol Oncol. 2000; 78(2):97-105. DOI: 10.1006/gyno.2000.5826. View
2.
Sato S, Makino H, Yajima A, Fukao A . Cervical cancer screening in Japan. A case-control study. Acta Cytol. 1997; 41(4):1103-6. DOI: 10.1159/000332795. View
3.
Sasieni P, Adams J, Cuzick J . Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003; 89(1):88-93. PMC: 2394236. DOI: 10.1038/sj.bjc.6600974. View
4.
Mitchell H, Medley G, Gordon I, Giles G . Cervical cytology reported as negative and risk of adenocarcinoma of the cervix: no strong evidence of benefit. Br J Cancer. 1995; 71(4):894-7. PMC: 2033741. DOI: 10.1038/bjc.1995.172. View
5.
Palli D, Carli S, Cecchini S, Venturini A, Piazzesi G, Buiatti E . A centralised cytology screening programme for cervical cancer in Florence. J Epidemiol Community Health. 1990; 44(1):47-51. PMC: 1060596. DOI: 10.1136/jech.44.1.47. View